Physician profile
Jesse Martin
NPI 1609174093
$2,497.86
in general payments reported to CMS, 2019-2025
25 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $257 · 2023: $454 · 2024: $450 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $413.73 | 2022-2025 | Breyanzi, Onureg |
| Kite Pharma, INC. | $304.09 | 2022-2025 | Yescarta |
| Incyte Corporation | $250.86 | 2021-2025 | Jakafi, Niktimvo |
| Rigel Pharmaceuticals, INC. | $239.19 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Abbvie INC. | $223.48 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $212.56 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Genentech USA, INC. | $140.82 | 2022-2025 | Venclexta, Polivy, Columvi |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2023 | |
| Legend Biotech USA INC. | $112.44 | 2023-2025 | Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $105.30 | 2021-2023 | Imbruvica |
| Sanofi-Aventis U.S. LLC | $42.50 | 2024-2025 | |
| Stemline Therapeutics INC. | $37.83 | 2024 | Elzonris |
| Regeneron Healthcare Solutions, INC. | $34.57 | 2025 | Lynozyfic |
| Genmab U.S., INC. | $31.54 | 2024 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $24.41 | 2025 | Copiktra |
| Astellas Pharma US INC | $23.45 | 2023 | |
| Syndax Pharmaceuticals, INC. | $22.63 | 2025 | |
| Paratek Pharmaceuticals, INC. | $21.32 | 2022 | |
| Karyopharm Therapeutics INC. | $19.27 | 2022 | |
| Amgen INC. | $18.42 | 2024 | Blincyto |
| Adc Therapeutics America, INC. | $18.29 | 2021 | |
| Servier Pharmaceuticals LLC | $18.26 | 2021 | |
| Daiichi Sankyo INC. | $18.20 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.